Skip to main content

Table 1 Study participants characteristics at baseline (n = 600)

From: Association of biochemical markers with bone marrow lesion changes on imaging—data from the Foundation for the National Institutes of Health Osteoarthritis Biomarkers Consortium

Age, mean ± SD years

61.5 ± 8.9

Female, %

58.8

Body mass index, mean ± SD kg/m2

30.7 ± 4.8

Right knee analyzed, %

322 (53.7%)

Kellgren/Lawrence grade, %

 1

75 (12.5%)

 2

306 (51%)

 3

219 (36.5%)

Race, %

 African American

109 (18.2%)

 Asian

5 (0.8%)

 Others

11 (1.8%)

 White

475 (79.2%)

Medication use, %

 Bisphosphonate in last year

42 (7.8%)

 PTH in last 6 months

2 (0.3%)

Biochemical markers, mean ± SD

 Serum CTX-I (ng/ml)

0.39 ± 0.21

 Serum NTX-I (nmole BCE)

15.11 ± 5.21

 Serum C1M (ng/ml)

49.87 ± 32.66

 Serum C2M (ng/ml)

0.48 ± 0.27

 Serum C3M (ng/ml)

8.26 ± 2.61

 Serum CRPM (ng/ml)

9.07 ± 8.13

 Serum hsPRO-C2 (ng/ml)a

3.72 ± 4.56

 Urinary CTX-II (μg/ml)

0.30 ± 0.19

 Urinary NTX-I (nmole BCE)

33.33 ± 17.70

 Urinary CTX-Iα (ng/ml)

0.43 ± 0.34

 Urinary CTX-Iβ (μg/L)

2.26 ± 1.76

  1. PTH parathyroid hormone, CTX-I serum C-terminal crosslinked telopeptide of type I collagen, NTX-I serum crosslinked N-telopeptide of type I collagen, CTX-II urinary CTX-Iα and CTX-Iβ, urinary NTX-I, urinary C-terminal crosslinked telopeptide of type II collagen, C1M, C2M, C3M serum type I, II, III collagen degradation mediated by matrix metalloproteinase (MMP) cleavage, hsPRO-C2 serum propeptide of type IIb collagen, CRPM serum metabolite of C-reactive protein
  2. an = 437
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us